Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma
Studying MALT lymphoma
Last synced from ClinicalTrials.gov
Key facts
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Intervention
- orelabrutinib combined with rituximab regimen(drug)
- Enrollment
- 51 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (18)
- Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
- Dongyang People's Hospital, Dongyang, China
- Affiliated Hangzhou First People's Hospital, Hangzhou, China
- Zhejiang cancer Hospital, Hangzhou, China
- Huzhou Central Hospital, Huzhou, China
- Affiliated Hospital of Jiaxing University, Jiaxing, China
- The Second Affiliated Hospital of Jiaxing University, Jiaxing, China
- Lishui central Hospital, Lishui, China
- the Affiliated Peopele'S Hospital of Ningbo University, Ningbo, China
- Quzhou People's Hospital, Quzhou, China
- Shaoxing Central Hospital, Shaoxing, China
- shaoxing People's Hospital, Shaoxing, China
- Taizhou Central Hospital, Taizhou, China
- Taizhou First People's Hospital, Taizhou, China
- Taizhou Hospital ofzhejiang Province, Taizhou, China
- +3 more locations on ClinicalTrials.gov
Collaborators
The Second Affiliated Hospital of Jiaxing University · Taizhou First People's Hospital · Huzhou Central Hospital · Zhejiang Cancer Hospital · Dongyang People's Hospital · Yuyao People's Hospital · Taizhou Hospital · Shaoxing Central Hospital · Affiliated Hospital of Jiaxing University · Shaoxing People's Hospital · Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University · The Central Hospital of Lishui City · Second Affiliated Hospital of Wenzhou Medical University · Ningbo People's Hospital · The People's Hospital of Quzhou · Zhejiang University · Zhuji People's Hospital of Zhejiang Province
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07022223 on ClinicalTrials.govOther trials for MALT lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07554898Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT LymphomaZhejiang Cancer Hospital
- RECRUITINGPHASE2NCT06510309Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaGottfried von Keudell, MD PhD
- RECRUITINGPHASE2NCT07441993Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07372365Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.The First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT06796998Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)Izidore Lossos, MD
- RECRUITINGNCT06712459Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone LymphomaInternational Extranodal Lymphoma Study Group (IELSG)
- ACTIVE NOT RECRUITINGPHASE2NCT07480863Treatment of BTKi+Hi-CVP Regimen for Previously Untreated MZLCancer Institute and Hospital, Chinese Academy of Medical Sciences
- ACTIVE NOT RECRUITINGPHASE2NCT07247383Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT LymphomaSecond Affiliated Hospital, School of Medicine, Zhejiang University